Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - fluconazole - oral capsule - 200mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - fluconazole - oral capsule - 200mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - fluconazole - oral capsule - 200mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - fluconazole - oral capsule - 200mg

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - fluconazole 200mg - capsule - 200 mg - active: fluconazole 200mg excipient: colloidal silicon dioxide erythrosine gelatin   indigo carmine lactose magnesium stearate maize starch methyl hydroxybenzoate   propyl hydroxybenzoate   purified water   sodium laurilsulfate     titanium dioxide   - fluconazole capsules are indicated for the treatment of cryptococcosis

Estats Units - anglès - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole tablets, usp are indicated for the treatment of: prophylaxis. fluconazole tablets, usp are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. coadministration of terfenadine is contraind

Estats Units - anglès - NLM (National Library of Medicine)

unit dose services - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 150 mg - fluconazole is indicated for the treatment of: - vaginal candidiasis (vaginal yeast infections due to ). candida - oropharyngeal and esophageal candidiasis. in open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of urinary tract infections, peritonitis, and systemic infections including candidemia, disseminated candidiasis, and pneumonia. candida candida - cryptococcal meningitis. before prescribing fluconazole for aids patients with cryptococcal meningitis, please see section. studies comparing fluconazole to amphotericin b in non-hiv infected patients have not been conducted. clinical studies fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology,

Estats Units - anglès - NLM (National Library of Medicine)

direct rx - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole 200 mg - fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration. fluconazole is designated chemically as 2,4-difluoro-α,α1-bis(1h-1,2,4-triazol-1-ylmethyl) benzyl alcohol with a molecular formula of c13h12f2n6o and molecular weight 306.3. the structural formula is: fluconazole usp is a white crystalline solid which is slightly soluble in water and saline. fluconazole tablets usp contain 50, 100, 150, or 200 mg of fluconazole usp and the following inactive ingredients: dibasic calcium phosphate anhydrous, ferric oxide (iron oxide, red), magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate, and starch. fluconazole tablets meets usp dissolution test 2. close

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - fluconazole 200mg - capsule - 200 mg - active: fluconazole 200mg excipient: colloidal silicon dioxide erythrosine gelatin   indigo carmine lactose magnesium stearate maize starch methyl hydroxybenzoate   propyl hydroxybenzoate   purified water   sodium laurilsulfate     titanium dioxide   - fluconazole capsules are indicated for the treatment of cryptococcosis

Estats Units - anglès - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - fluconazole (unii: 8vzv102jfy) (fluconazole - unii:8vzv102jfy) - fluconazole tablets are indicated for the treatment of: prophylaxis: fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. fluconazole is contraindicated in patients who have shown hypersensitivity to fluconazole or to any of its excipients. there is no information regarding cross-hypersensitivity between fluconazole and other azole antifungal agents. caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles. coadministration of terfenadine is contraindicated in